%0 Journal Article
%A Dimopoulos, Meletios A
%A Dytfeld, Dominik
%A Grosicki, Sebastian
%A Moreau, Philippe
%A Takezako, Naoki
%A Hori, Mitsuo
%A Leleu, Xavier
%A LeBlanc, Richard
%A Suzuki, Kenshi
%A Raab, Marc-Steffen
%A Richardson, Paul G
%A Popa McKiver, Mihaela
%A Jou, Ying-Ming
%A Shelat, Suresh G
%A Robbins, Michael
%A Rafferty, Brian
%A San-Miguel, Jesús
%T Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
%J The New England journal of medicine
%V 379
%N 19
%@ 1533-4406
%C Waltham, Mass.
%I MMS
%M DKFZ-2019-00106
%P 1811 - 1822
%D 2018
%X The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival.A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K Immunologic Factors (NLM Chemicals)
%K elotuzumab (NLM Chemicals)
%K Thalidomide (NLM Chemicals)
%K Dexamethasone (NLM Chemicals)
%K pomalidomide (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30403938
%R 10.1056/NEJMoa1805762
%U https://inrepo02.dkfz.de/record/142330